Channels - Duration-Dependent Adverse Events of Systemic Glucocorticosteroids in Atopic Dermatitis: A Nationwide Claims Cohort Study :: FRELIP Discovery

Similar Items: Duration-Dependent Adverse Events of Systemic Glucocorticosteroids in Atopic Dermatitis: A Nationwide Claims Cohort Study

Quick Look
Incidence of Skin Infections in Patients with Atopic Dermatitis Treated with Topical Medications: A Cohort Study Using Japanese Claims Data
Quick Look
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)
Quick Look
Dupilumab Can Be Effective for Immune-Related Adverse Event Dermatitis: A Case Report and Review of the Literature
Quick Look
Corticosteroid Phobia in Patients with Atopic Dermatitis: A Narrative Review
Quick Look
Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region
Quick Look
Review on the Application of Biologic Factors in Atopic Dermatitis and Chronic Spontaneous Urticaria
Quick Look
The Importance of Achieving High Treatment Targets in Atopic Dermatitis: A Narrative Review
Quick Look
Do Medication Beliefs Influence Adherence to Topical Therapies in Patients With Atopic Dermatitis?
Quick Look
Topical Corticosteroid Phobia in Childhood Atopic Dermatitis: A Study Using the TOPICOP Score
Quick Look
Mental Health Among Caregivers of Children With Atopic Dermatitis: A Systematic Review With Meta‐Analysis
Quick Look
Evolving Research Hotspots and Emerging Trends in Atopic Dermatitis and Inflammatory Bowel Disease: A Bibliometric Analysis
Quick Look
Optimizing Abrocitinib Use for Atopic Dermatitis in India: Expert Recommendations for Patient Selection, Dosing, and Long‑Term Remission
Quick Look
Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria
Quick Look
Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)
Quick Look
Pingueculitis in psoriasis patient on secukinumab – An unreported adverse event
Quick Look
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence
Quick Look
Biochemical Mechanisms Mediating the Immunomodulatory and Anti-Atopic Dermatitis Effects of GammaQ in a DNCB-Induced BALB/c Mouse Model
Quick Look
Corrigendum to “Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials”
Quick Look
Prevalence and Burden of Somatic Symptom Disorder in Atopic Dermatitis and Chronic Pruritus—The Persistent Somatic Symptoms Across Diseases: Pruritus (SOMA.PRU) Study
Quick Look
REVEAL AD ‐ Prevalence of Moderate and Severe Atopic Dermatitis in Ireland: A Cross‐ Sectional, Real World Study of a Secondary Care Population
Quick Look
Patient‐Centred Care in Atopic Dermatitis: Digital Communication, Misinformation, and Global Perspectives From the Pacecad Sessions (Isad Rajka Symposium, Melbourne 2025)
Quick Look
Achieving Canadian Treat-to-Target Criteria in Moderate-to-Severe Atopic Dermatitis: A Retrospective Analysis of Outcomes from Real-World Canadian Practice
Quick Look
Letter to the Editor Regarding “Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis”
Quick Look
Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis